INDOCO REMEDIES
INDOCO · NSE
209.50
-4.25 (-1.99%)
as of 29 Oct 2026 close
Open
214.25
High
216.00
Low
208.20
Prev close
213.75
52w high
288.00
06 Nov 2025
52w low
162.19
30 Mar 2026
VWAP
210.94
Delivery %
53.3%
of volume
Volume 1.38 L · turnover ₹2.91 Cr · NSE bhavcopy (official close), adjusted for splits/bonuses · history since 04 Jan 2010
- ISIN
- INE873D01024
- Series
- EQ
- Listed on NSE
- 14 Jan 2005
- Face value
- ₹2
- F&O
- No
Source: NSE equity master · as of 30 Oct 2026
Daily · NSE EOD
Quarterly results · Standalone · latest 30 Sept 2026
filed 27 Oct 2026, 03:17 pm IST| ₹ crore | Sept 26* |
|---|---|
| Revenue | 452 |
| Other income | 5 |
| Total expenses | 459 |
| Operating margin | 17.1% |
| Finance costs | 20 |
| Depreciation | 28 |
| Profit before tax | 35 |
| Tax | 4 |
| Net profit | 31 |
| Net margin | 6.8% |
| EPS (₹) | 3.32 |
Source and definitions
NSE financial-results filings (XBRL / integrated filing). Figures exactly as filed with NSE in the company's results, converted to ₹ crore from the filing's own rounding. Operating margin = (PBT + finance costs + depreciation − other income) ÷ revenue. Net margin = net profit ÷ revenue. * = unaudited quarter. Consolidated figures are shown when the company files them; otherwise standalone.
Coming next in fundamentals
Arrives in Phase 2. Nothing here is estimated or filled in — we only show data we have.
- P/E, P/B, EV/EBITDA, ROE, ROCE (needs balance sheet + market cap)
- FII / DII / mutual fund split (from shareholding XBRL)
- Peer comparison